Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Evolving patient management in metastatic and non-metastatic castration-resistant prostate cancer

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.11.12
Views: 6445

Professor Noel Clarke, Dr Heather Payne, Prof Karim Fizazi,Prof John Fitzpatrick, Prof Bertrand Tombal

Professor Noel Clarke - Honorary Professor in Urological Cancer/Consultant Urologist, Manchester University, talks to ecancer TV with Dr Heather Payne - University College Hospital, London, Prof Karim Fizazi - Institut Gustave Roussy, France, Prof John Fitzpatrick - School of Medicine & Medical Science Mater Misericordiae University Hospital & University College Dublin, Ireland and Prof Bertrand Tombal - Saint-Luc Hospital, Catholic University of Leuven, Belgium, about recent advances in the management of patients with prostate cancer.


The panel discusses who to treat and who not to treat, with emphasis on first-line therapy. Experts highlight recent data which suggest that the duration of hormonal therapy is an indicator for the response to second-line therapy. Results from the 301 study and the relationship between performance status and ECOG status are also discussed with a focus on individualised treatment. Experts debate strategies to determine patient responses, and highlight the need for trials investigating the value of biopsies and biomarkers with a focus on heterogeneity of tumour cells. 


The experts discuss whether anti-androgen therapy should be used upfront or after cytotoxic treatment and agree that further trials are still required examining cross resistance. ‘Combination’ treatment rather than sequence of drugs is also highlighted as an important option.


Skeletal integrity is discussed, with the emphasis on the need for supportive care for bone. Bisphosphonates and denosumab are discussed, together with the results of last year’s study with alpharadin which suggested a direct anti-cancer effect. Overall, there is a need to develop drugs which can prevent cancer cells from binding to the bone to improve patient outcomes.


This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation